Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Rabe (Kiel, Germany), G. Brusselle (Ghent, Belgium), M. Castro (St. Louis, United States of America), L. Sher (Rolling Hills Estates, United States of America), H. Zhu (Bridgewater, United States of America), Q. Dong (Bridgewater, United States of America), J. Hamilton (Tarrytown, United States of America), W. Brian (Bridgewater, United States of America), A. Jagerschmidt (Chilly-Mazarin, France), G. Pirozzi (Bridgewater, United States of America), N. Amin (Tarrytown, United States of America), M. Ruddy (Tarrytown, United States of America), B. Akinlade (Tarrytown, United States of America), N. H. Graham (Tarrytown, United States of America), A. Teper (Bridgewater, United States of America). Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE. 5003

Member's Comments

No comment yet.

Related content which might interest you: Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 Efficacy of dupilumab in patients with oral corticosteroid (OCS)-dependent, severe asthma with and without an allergic phenotype: phase 3 LIBERTY ASTHMA VENTURE Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Impact of severe exacerbations on lung function in dupilumab-treated patients: LIBERTY ASTHMA QUEST Source: Virtual Congress 2021 – Pearls in immunology, outcome studies and clinical trials in asthma, alpha-1 antitrypsin deficiency and COPD Year: 2021 Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Exacerbation burden in mild asthma: Evidence from the NOVELTY study Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Eosinophilic phenotype classification of patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2021 – Biomarkers to phenotype asthma: prediction of exacerbations Year: 2021 Dupilumab improves asthma-related patient reported outcomes in asthma patients with chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST Source: International Congress 2018 – Novel immunology-based therapies in asthma and COPD Year: 2018 Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018 Dysinapsis in COPD and ASTHMA Source: Eur Respir J 2003; 22: Suppl. 45, 416s Year: 2003 Montelukast reduces viral-induced asthma exacerbations: the PREVIA study Source: Eur Respir J 2004; 24: Suppl. 48, 212s Year: 2004 Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY Source: Virtual Congress 2020 – New tools for risk stratification of obstructive diseases Year: 2020 Factors associated with exacerbations in patients with COPD: NOVELTY study Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020 Long-term haemodynamic response in patients with pulmonary hypertension inhaling iloprost (AIR-2 STUDY) Source: Eur Respir J 2003; 22: Suppl. 45, 562s Year: 2003 DOES THE BENEFIT FROM PULMONARY REHABILITATION DIFFER BETWEEN PHENOTYPES IN COPD? Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020 Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017 EOSINOPHIL COUNT AND FeNO AS PREDICTORS OF EXACERBACTIONS IN COPD Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 The relationship between persistent systemic inflammation and symptoms of depression among patients with COPD in the ECLIPSE cohort Source: Annual Congress 2013 –The best abstracts in extra-pulmonary features and pulmonary rehabilitation Year: 2013